Identify cognitive decline in Parkinsons
- Trial ID
- NCT03402919
- Official Title
- The Comprehensive Assessment of Neurodegeneration and Dementia Study
- Goal
- Identify cognitive decline in Parkinsons
- Status
- RECRUITING
- Sponsor
- McGill University
- Study Type
- OBSERVATIONAL
- Enrollment
- 1573 participants
- Conditions
- Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD), Lewy Body Disease(LBD), Mixed Dementia, Frontotemporal Dementia (FTD), Alzheimer Disease (AD), Cognitively Unimpaired, Subjective Cognitive Decline (SCD)
Summary For Families
The goal is to map how cognition and brain changes progress across Parkinson's and related conditions, so clinicians can better detect and track mild cognitive impairment and dementia in people with PD. Instead of testing a drug, participants get detailed neuropsychological testing, MRI scans, and reports from a study partner to link symptoms with brain imaging and build a comprehensive profile over time. The study seeks adults 50 to 90 who speak English or French, can travel to the site and bring a study partner, and includes people from cognitively unimpaired to PD with MCI, while excluding those with other major brain diseases, recent symptomatic stroke, ongoing substance abuse, or MRI contraindications.
Locations
- University of Calgary, Calgary, Alberta, Canada
- University of Alberta Hospital, Edmonton, Alberta, Canada
- Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada
- Island Health, Victoria, British Columbia, Canada
- Veteran's Memorial Building, Halifax, Nova Scotia, Canada
- Hamilton General Hospital, Hamilton, Ontario, Canada
- St. Joseph's Health Care London, London, Ontario, Canada
- Gait and Brain Lab, London, Ontario, Canada
- Bruyère Research Institute, Ottawa, Ontario, Canada
- Kawartha Centre, Peterborough, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- University Health Network Memory Clinic, Toronto, Ontario, Canada
- Baycrest Clinical Unit, Toronto, Ontario, Canada
- University of Waterloo, Waterloo, Ontario, Canada
- Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
- Jewish General Hospital/McGill Memory Clinic, Montreal, Quebec, Canada
- Clinique de cognition Institut universitaire de gériatrie de Montréal, Montreal, Quebec, Canada
- Hôpital Enfant-Jésus, Québec, Quebec, Canada
- Centre de recherche sur le vieillissement CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to map how cognition and brain changes progress across Parkinson's and related conditions, so clinicians can better detect and track mild cognitive impairment and dementia in people with PD. Instead of testing a drug, participants get detailed neuropsychological testing, MRI scans, and reports from a study partner to link symptoms with brain imaging and build a comprehensive profile over time. The study seeks adults 50 to 90 who speak English or French, can travel to the site and bring a study partner, and includes people from cognitively unimpaired to PD with MCI, while excluding those with other major brain diseases, recent symptomatic stroke, ongoing substance abuse, or MRI contraindications.
- Who can participate?
- Participants must be between 50 Years and 90 Years.
- Where is this trial located?
- This trial is recruiting at 19 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 5 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.